STAT5A and neoplasm: Importantly, in Tet2 or Stat5a deficiency cells-derived tumors, the combination of VC and anti-PD-L1 had no obvious changes in tumor burdens as compared to single VC or anti-PD-L1 therapy (Fig. 10a–d).